{"id":30033,"date":"2022-01-03T08:10:06","date_gmt":"2022-01-03T06:10:06","guid":{"rendered":"https:\/\/aluksne.lv\/?p=30033"},"modified":"2022-01-07T13:23:30","modified_gmt":"2022-01-07T11:23:30","slug":"kas-jazina-par-balstvakcinaciju","status":"publish","type":"post","link":"https:\/\/aluksne.lv\/index.php\/2022\/01\/03\/kas-jazina-par-balstvakcinaciju\/","title":{"rendered":"Kas j\u0101zina par balstvakcin\u0101ciju"},"content":{"rendered":"

\"Kas<\/a>Balstvakcin\u0101cija ir viens no efekt\u012bv\u0101kajiem risin\u0101jumiem c\u012b\u0146\u0101 pret augstu saslimst\u012bbu ar Covid-19, t\u0101 mazina transmisiju \u012bstermi\u0146\u0101 un potenci\u0101li ar\u012b ilgtermi\u0146\u0101. \u0160obr\u012bd balstvakcin\u0101cija pret Covid-19 ir pieejama pla\u0161am sabiedr\u012bbas lokam. <\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Balstvakc\u012bnas m\u0113r\u0137is ir stiprin\u0101t cilv\u0113ku im\u016bnaizsardz\u012bbu, tostarp ar\u012b pret jaun\u0101kajiem Covid-19 v\u012brusa variantiem. Balstvakcin\u0101cija pasarg\u0101 no smagas slim\u012bbas gaitas un n\u0101ves, ta\u010du t\u0101 piln\u012bb\u0101 nenodro\u0161ina iesp\u0113ju neinfic\u0113ties ar v\u012brusu visp\u0101r. Jo liel\u0101ks iedz\u012bvot\u0101ju skaits b\u016bs balstvakcin\u0113jies, jo liel\u0101ka iesp\u0113ja, ka slim\u012bba maz\u0101k izplat\u012bsies sabiedr\u012bb\u0101.<\/p>\n

 <\/p>\n

Balstvakcin\u0101cija sp\u0113j pastiprin\u0101t cilv\u0113ka im\u016bno atbildi uzreiz, aizsarg\u0101jo\u0161ais efekts p\u0113c vakcin\u0101cijas veik\u0161anas ir jau n\u0101kamaj\u0101 dien\u0101.<\/p>\n

 <\/p>\n

Balstvakcin\u0101ciju aicin\u0101m doties sa\u0146emt uzreiz, neatliekot uz v\u0113l\u0101ku laiku.\u00a0<\/p>\n

 <\/p>\n

\u012apa\u0161i aicin\u0101m neatlikt balstvakcin\u0101cijas sa\u0146em\u0161anu riska grup\u0101s eso\u0161\u0101s personas, personas no 40 gadu vecuma un personas, kas pirmreiz\u0113jo vakcin\u0101ciju sa\u0146\u0113mu\u0161as pavasar\u012b vai vasaras s\u0101kum\u0101.<\/p>\n

 <\/p>\n

Balstvakc\u012bna \u012bpa\u0161i nepiecie\u0161ama cilv\u0113kiem ar nov\u0101jin\u0101tu imunit\u0101ti<\/strong><\/p>\n

 <\/p>\n

Im\u016bnsupres\u0113tiem jeb cilv\u0113kiem ar nov\u0101jin\u0101tu imunit\u0101ti balstvakc\u012bnas sa\u0146em\u0161ana tiek \u012bpa\u0161i rekomend\u0113ta, ar\u012b p\u0113c div\u0101m dev\u0101m un izslimo\u0161anas. T\u0101s ir personas ar HIV, onkolo\u0123isk\u0101m saslim\u0161an\u0101m, org\u0101nu vai cilmes \u0161\u016bnu transplant\u0101cij\u0101m, ilgsto\u0161u dial\u012bzi, k\u0101 ar\u012b atsevi\u0161\u0137u medikamentu lietot\u0101ji. \u0160ai sabiedr\u012bbas grupai Imuniz\u0101cijas valsts padome prim\u0101ro vakcin\u0101ciju ir noteikusi ar tr\u012bs dev\u0101m, proti, 21-28 dien\u0101s p\u0113c pirm\u0101s potes bija nepiecie\u0161ams sa\u0146emt otro vakc\u012bnu un v\u0113l p\u0113c 28 dien\u0101m \u2013 tre\u0161o devu. Attiec\u012bgi, balstvakc\u012bna jeb ceturt\u0101 deva \u0161iem cilv\u0113kiem ieteicama se\u0161us m\u0113ne\u0161us p\u0113c tre\u0161\u0101s devas sa\u0146em\u0161anas.<\/p>\n

\u00a0<\/strong><\/p>\n

Balstvakcin\u0101cija var\u0113tu pasarg\u0101t no smagas Covid-19 v\u012brusa Omicron varianta slim\u012bbas gaitas<\/strong><\/p>\n

 <\/p>\n

P\u0113c izskan\u0113ju\u0161\u0101s inform\u0101cijas par jauno Covid-19 v\u012brusa Omicron variantu ir par\u0101d\u012bju\u0161ies da\u017e\u0101di viedok\u013ci un versijas par to, k\u0101 \u0161is v\u012brusa variants izplat\u012bsies un vai balstvakcin\u0101cija sp\u0113s no t\u0101 aizsarg\u0101t pietieko\u0161i efekt\u012bvi. Speci\u0101listi \u0161obr\u012bd dom\u0101, ka balstvakc\u012bna var\u0113tu pasarg\u0101t no smagas slim\u012bbas gaitas un non\u0101k\u0161anas intens\u012bvaj\u0101 terapij\u0101, ja cilv\u0113ks infic\u0113jas ar Omicron variantu. Ta\u010du balstvakc\u012bna piln\u012bb\u0101 nenodro\u0161ina iesp\u0113ju neinfic\u0113ties ar v\u012brusu visp\u0101r.<\/p>\n

Speci\u0101listi apstiprina – lai gan \u0161obr\u012bd ir daudz neatbild\u0113tu jaut\u0101jumu saist\u012bb\u0101 ar jauno Omicron variantu, sa\u0146emot balstvakc\u012bnu ar jau eso\u0161aj\u0101m vakc\u012bn\u0101m jebkur\u0101 vecum\u0101, palielin\u0101s cilv\u0113ka im\u016bnsist\u0113mas aizsardz\u012bbas sp\u0113jas.<\/p>\n

\u00a0<\/strong><\/p>\n

Balstvakc\u012bnas ievad\u012b\u0161anas laiks atkar\u012bgs no prim\u0101raj\u0101 vakcin\u0101cij\u0101 sa\u0146emtaj\u0101m vakc\u012bn\u0101m<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Tiem iedz\u012bvot\u0101jiem, kuri vakcin\u0113ju\u0161ies ar \u201cJohnsons&Johnsons\u201d \u201cJanssen\u201d – p\u0113c balstvakc\u012bnas j\u0101dodas asto\u0146as ned\u0113\u013cas p\u0113c sa\u0146emt\u0101s potes. Savuk\u0101rt, ja \u201cJanssen\u201d vakc\u012bnas sa\u0146\u0113m\u0113js ir ar\u012b slimojis ar Covid-19, tad p\u0113c papildu devas j\u0101dodas se\u0161us m\u0113ne\u0161us p\u0113c p\u0101rslimo\u0161anas.<\/p>\n

 <\/p>\n

Ja prim\u0101raj\u0101 vakcin\u0101cij\u0101 abas potes bija vakc\u012bnas \u201cVaxzevria\u201d (\u201cAstraZeneca\u201d), \u201cSpikevax\u201d (\u201cModerna\u201d)\u00a0 vai \u201cComirnaty\u201d (\u201cPfizer-BioNTech\u201d), balstvakc\u012bnu iesp\u0113jams sa\u0146emt tr\u012bs m\u0113ne\u0161us p\u0113c otr\u0101s potes sa\u0146em\u0161anas.<\/p>\n

 <\/p>\n

Balstvakc\u012bnas veids atkar\u012bgs no jau sa\u0146emtaj\u0101m vakc\u012bn\u0101m<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Ja cilv\u0113kam pirmreiz\u0113j\u0101 vakcin\u0101cij\u0101 abas bija \u201cModerna\u201d ra\u017eot\u0101s \u201cSpikevax\u201d, tad balstvakc\u012bna b\u016bs jau min\u0113t\u0101 \u201cSpikevax\u201d vai \u201cComirnaty\u201d (\u201cPfizer-BioNTech\u201d); ja abas s\u0101kotn\u0113j\u0101s vakc\u012bnas devas bija \u201cComirnaty\u201d, tad balstvakc\u012bna b\u016bs \u201cComirnaty\u201d vai \u201cSpikevax\u201d.<\/p>\n

 <\/p>\n

Ja pirmreiz\u0113j\u0101 vakcin\u0101cij\u0101 tika sa\u0146emtas k\u0101da no v\u012brusa vektora vakc\u012bn\u0101m, proti, \u201cAstra Zeneca\u201d ra\u017eot\u0101 vakc\u012bna \u201cVaxzevria\u201d vai \u201cJohhson&Johnson\u201d ra\u017eot\u0101 vakc\u012bna \u201cJanssen\u201d, tad balsvakcin\u0101cij\u0101 tiek izmantota k\u0101da no zi\u0146ne\u0161u jeb mRns vakc\u012bn\u0101m (\u201cSpikevax\u201d vai \u201cComirnaty\u201d). \u0160\u0101da vakc\u012bnu kombin\u0101cija nodro\u0161ina augst\u0101ku aizsardz\u012bbu pret Covid-19.<\/p>\n

 <\/p>\n

T\u0101tad, ja pirm\u0101s divas potes bija \u201cVaxzevria\u201d, tad balstvakc\u012bna b\u016bs \u201cSpikevax\u201d, \u201cComirnaty\u201d vai \u201cVaxzevria\u201d. Tikm\u0113r \u201cJanssen\u201d tiek stiprin\u0101ta ar \u201cSpikevax\u201d vai \u201cComirnaty\u201d.<\/p>\n

Gad\u012bjumos, ja prim\u0101raj\u0101 vakcin\u0101cij\u0101 \u201cVaxzevria\u201d bija pirm\u0101 deva, bet otr\u0101 deva \u201cComirnaty\u201d vai \u201cSpikevax\u201d, tad balstvakc\u012bna b\u016bs \u201cSpikevax\u201d vai Comirnaty\u201d.<\/p>\n

 <\/p>\n

Vakc\u012bnu \u201cjauk\u0161ana\u201d nav jaunums, \u0161\u0101da pieeja ir izmantota jau agr\u0101k, turkl\u0101t Eiropas Z\u0101\u013cu a\u0123ent\u016bra, izp\u0113tot valstu pieredzes, apstiprina, ka \u0161\u0101da metode nepiecie\u0161am\u012bbas gad\u012bjum\u0101 ir at\u013cauta. Vienlaikus, ja, piem\u0113ram, persona s\u0101kotn\u0113ji ir sa\u0146\u0113musi divas \u201cComirnaty\u201d (\u201cPfizer-BioNTech\u201d) devas, tad, atkar\u012bb\u0101 no pieejam\u012bbas, ar\u012b balstvakc\u012bnai izmantos to pa\u0161u veidu.<\/p>\n

\u00a0<\/strong><\/p>\n

Doties sa\u0146emt balstvakc\u012bnu var gan piesakoties, gan, izmantojot dz\u012bv\u0101s rindas iesp\u0113jas<\/strong><\/p>\n

 <\/p>\n

Sa\u0146emt balstvakc\u012bnu var gan re\u0123istr\u0113joties iepriek\u0161 vietn\u0113 manavakcina.lv, zvanot 8989 vai pie sava \u0123imenes \u0101rsta.<\/p>\n

 <\/p>\n

Ir atsevi\u0161\u0137i vakcin\u0101cijas punkti, kur vakc\u012bnu var sa\u0146emt ar\u012b bez iepriek\u0161\u0113ja pieraksta, dz\u012bvaj\u0101 rind\u0101 – piem\u0113ram, lielajos vakcin\u0101cijas centros R\u012bg\u0101, pagaidu vakcin\u0101cijas punktos, izbraukuma vakcin\u0101cij\u0101.<\/p>\n

 <\/p>\n

P\u0113c balstvakc\u012bnas sa\u0146em\u0161anas der\u012bgi b\u016bs divi sertifik\u0101ti<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Digit\u0101lais sertifik\u0101ts, kas sa\u0146emts p\u0113c prim\u0101r\u0101 vakcin\u0101cijas kursa pabeig\u0161anas, turpin\u0101s darboties. Sertifik\u0101t\u0101 par\u0101d\u012bsies atz\u012bme, kad veikta balstvakcin\u0101cija un vakc\u012bnas nosaukums. Savuk\u0101rt p\u0113c balstvakc\u012bnas sa\u0146em\u0161anas s\u0101ks darboties ar\u012b balstvakcin\u0101cijas sertifik\u0101ts, un lieto\u0161anai der\u012bgi b\u016bs abi dokumenti.<\/p>\n

 <\/p>\n

Balstvakc\u012bnas sa\u0146em\u0161anas nosac\u012bjumi: <\/strong><\/p>\n